The first half of the prize has been awarded jointly to Ireland born William Campbell and Japanese scientist Satoshi Omura by the Nobel Assembly at Karolinska Institutet for
The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako’s portfolio of companion diagnostics and the company’s leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Under FDA’s accelerated approval regulations, this
The SOLUTION clinical study is designed to evaluate the efficacy and safety of Sollpura, a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived,
It aims to lower the risks of disease progression and hospitalization for worsening PAH, and enhance exercise ability. The approval followed a study in which the Letairis/tadalafil combination
Ace-ER is designed for the replacement of the deficient sialic acid substrate in patients with GNE Myopathy. A defect in the biosynthetic pathway for sialic acid, with onset
Etanercept is a tumor necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis. Sandoz head of global biopharmaceutical &
Moxatag is indicated to treat tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adult and pediatric patients of 12 years or more. Vernalis paid an undisclosed up-front cash
The move forms part of the company’s "Fit for 2018" strategic transformation and growth program, which includes the focus on innovative, technology-driven businesses as well as the modernization
The funds were raised in a mezzanine financing round from all its existing investors, including Nordic investors Investinor and Industrifonden. Pharmalink will use the money to prepare a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.